Purpose: To explore the association between CYP3A4 and CYP3A5 gene polymorphisms and blood pressure response to amlodipine among participants from the African-American Study of Kidney Disease and Hypertension Trial randomized to amlodipine (n = 164). Methods: Cox proportional hazards models were used to determine the risk of reaching a target mean arterial pressure (MAP) of ≤107 mm Hg by CYP3A4 (A–392G and T16090C) and CYP3A5 (A6986G) gene polymorphisms, stratified by MAP randomization group (low or usual) and controlling for other predictors for blood pressure response. Results: Women randomized to a usual MAP goal with an A allele at CYP3A4 A–392G were more likely to reach a target MAP of 107 mm Hg. The adjusted hazard ratio (AA/AG compared to GG) with 95% confidence interval was 3.41 (1.20–9.64; p = 0.020). Among participants randomized to a lower MAP goal, those with the C allele at CYP3A4 T16090C were more likely to reach target MAP: The adjusted hazard ratio was 2.04 (1.17–3.56; p = 0.010). After adjustment for multiple testing using a threshold significance level of p = 0.016, only the CYP3A4 T16090C SNP remained significant. CYP3A5 A6986G was not associated with blood pressure response. Conclusions: Our findings suggest that blood pressure response to amlodipine among high-risk African-Americans appears to be determined by CYP3A4 genotypes, and sex specificity may be an important consideration. Clinical applications of CYP3A4 genotype testing for individualized treatment regimens warrant further study.

Keywords:
Pharmacogenetics, Hypertension, Amlodipine, Renal failure, CYP3A polymorphisms, AASK, African-Americans
1.
Rizzo JA, Simons WR: Variations in compliance among hypertensive patients by drug class: implications for health care costs. Clin Ther 1997;19:1446–1457.
2.
Appel LJ, et al: The rationale and design of the AASK cohort study. J Am Soc Nephrol 2003;14(suppl 2):S166–S172.
3.
Chobanian AV, et al: The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 Report. JAMA 2003;289:2560–2572.
4.
McClellan W, Tuttle E, Issa A: Racial differences in the incidence of hypertensive end-stage renal disease are not entirely explained by differences in the prevalence of hypertension. Am J Kidney Dis 1988;12:285–290.
5.
Safford MM, et al: Understanding racial disparities in hypertension control: intensity of hypertension medication treatment in the REGARDS study. Ethn Dis 2007;17:421–426.
6.
Hustert E, et al: The genetic determinants of the CYP3A5 polymorphism. Pharmacogenetics 2001;11:773–779.
7.
Kreutz R, et al: The role of the cytochrome P450 3A5 enzyme for blood pressure regulation in the general Caucasian population. Pharmacogenet Genomics 2005;15:831–837.
8.
Lamba JK, et al: Genetic contribution to variable human CYP3A-mediated metabolism. Adv Drug Deliv Rev 2002;54:1271–1294.
9.
Park JY, et al: Effect of CYP3A5*3 genotype on the pharmacokinetics and pharmacodynamics of alprazolam in healthy subjects. Clin Pharmacol Ther 2006;79:590–599.
10.
Kim KA, et al: Effect of polymorphic CYP3A5 genotype on the single-dose simvastatin pharmacokinetics in healthy subjects. J Clin Pharmacol 2007;47:87–93.
11.
Kim KA, et al: Effect of CYP3A5*3 genotype on the pharmacokinetics and pharmacodynamics of amlodipine in healthy Korean subjects. Clin Pharmacol Ther 2006;80:646–656.
12.
Davis BR, et al: Antihypertensive therapy, the α-adducin polymorphism, and cardiovascular disease in high-risk hypertensive persons: the Genetics of Hypertension-Associated Treatment Study. Pharmacogenomics J 2007;7:112–122.
13.
Brooks BA, et al: The gene CYP3 encoding P450pcn1 (nifedipine oxidase) is tightly linked to the gene COL1A2 encoding collagen type 1 α on 7q21-q22.1. Am J Hum Genet 1988;43:280–284.
14.
Cushman WC, et al: Regional and racial differences in response to antihypertensive medication use in a randomized controlled trial of men with hypertension in the United States. Department of Veterans Affairs Cooperative Study Group on Antihypertensive Agents. Arch Intern Med 2000;160:825–831.
15.
Damasceno A, et al: Efficacy of captopril and nifedipine in black and white patients with hypertensive crisis. J Hum Hypertens 1997;11:471–476.
16.
Weir MR, et al: Influence of race and dietary salt on the antihypertensive efficacy of an angiotensin-converting enzyme inhibitor or a calcium channel antagonist in salt-sensitive hypertensives. Hypertension 1998;31:1088–1096.
17.
Guo LQ, et al: Different roles of pummelo furanocoumarin and cytochrome P450 3A5*3 polymorphism in the fate and action of felodipine. Curr Drug Metab 2007;8:623–630.
18.
Fukuda T, et al: CYP3A5 genotype did not impact on nifedipine disposition in healthy volunteers. Pharmacogenomics J 2004;4:34–39.
19.
Ball SE, et al: Population distribution and effects on drug metabolism of a genetic variant in the 5′ promoter region of CYP3A4. Clin Pharmacol Ther 1999;66:288–294.
20.
Wright JT Jr, et al: Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial. JAMA 2002;288:2421–2431.
21.
Agodoa LY, et al: Effect of ramipril vs. amlodipine on renal outcomes in hypertensive nephrosclerosis: a randomized controlled trial. JAMA 2001;285:2719–2728.
22.
Norris KC, et al: Baseline predictors of renal disease progression in the African-American Study of Hypertension and Kidney Disease. J Am Soc Nephrol 2006;17:2928–2936.
23.
Bhatnagar V, et al: Angiotensin-converting enzyme gene polymorphism predicts the time-course of blood pressure response to angiotensin-converting enzyme inhibition in the AASK trial. J Hypertens 2007;25:2082–2092.
24.
Bhatnagar V, et al: G-protein-coupled receptor kinase 4 polymorphisms and blood pressure response to metoprolol among African-Americans: sex specificity and interactions. Am J Hypertens 2009;22:332–338.
25.
Kuehl P, et al: Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nat Genet 2001;27:383–391.
26.
Le Corre P, et al: Human sympathetic activation by α2-adrenergic blockade with yohimbine: bimodal, epistatic influence of cytochrome P450-mediated drug metabolism. Clin Pharmacol Ther 2004;76:139–153.
27.
Rebbeck TR, et al: Modification of clinical presentation of prostate tumors by a novel genetic variant in CYP3A4. J Natl Cancer Inst 1998;90:1225–1229.
28.
Nievergelt CM, Libiger O, Schork NJ: Generalized analysis of molecular variance. PLoS Genet 2007;3:e51.
29.
Contreras G, et al: Blood pressure control, drug therapy, and kidney disease. Hypertension 2005;46:44–50.
30.
Amirimani B, et al: Increased transcriptional activity of the CYP3A4*1B promoter variant. Environ Mol Mutagen 2003;42:299–305.
31.
Anglicheau D, et al: Consequences of genetic polymorphisms for sirolimus requirements after renal transplant in patients on primary sirolimus therapy. Am J Transplant 2005;5:595–603.
32.
Hesselink DA, et al: Genetic polymorphisms of the CYP3A4, CYP3A5, and MDR-1 genes and pharmacokinetics of the calcineurin inhibitors cyclosporine and tacrolimus. Clin Pharmacol Ther 2003;74:245–254.
33.
Wei-lin W, et al: Tacrolimus dose requirement in relation to donor and recipient ABCB1 and CYP3A5 gene polymorphisms in Chinese liver transplant patients. Liver Transpl 2006;12:775–780.
34.
Wandel C, et al: CYP3A activity in African-American and European-American men: population differences and functional effect of the CYP3A4*1B5-promoter region polymorphism. Clin Pharmacol Ther 2000;68:82–91.
35.
Meibohm B, Beierle I, Derendorf H: How important are gender differences in pharmacokinetics? Clin Pharmacokinet 2002;41:329–342.
36.
Cummins CL, Wu CY, Benet LZ: Sex-related differences in the clearance of cytochrome P450 3A4 substrates may be caused by P-glycoprotein. Clin Pharmacol Ther 2002;72:474–489.
37.
Schirmer M, et al: Sex-dependent genetic markers of CYP3A4 expression and activity in human liver microsomes. Pharmacogenomics 2007;8:443–453.
38.
Kadlubar FF, et al: The CYP3A4*1B variant is related to the onset of puberty, a known risk factor for the development of breast cancer. Cancer Epidemiol Biomarkers Prev 2003;12:327–331.
39.
Lai J, et al: CYP gene polymorphisms and early menarche. Mol Genet Metab 2001;74:449–457.
40.
Xin X, et al: Association study of four activity SNPs of CYP3A4 with the precocious puberty in Chinese girls. Neurosci Lett 2005;381:284–288.
41.
Chu W, et al: Association between CYP3A4 genotype and risk of endometrial cancer following tamoxifen use. Carcinogenesis 2007;28:2139–2142.
42.
Plummer SJ, et al: CYP3A4 and CYP3A5 genotypes, haplotypes, and risk of prostate cancer. Cancer Epidemiol Biomarkers Prev 2003;12:928–932.
43.
Bharucha AE, et al: Relationship of cytochrome P450 pharmacogenetics to the effects of yohimbine on gastrointestinal transit and catecholamines in healthy subjects. Neurogastroenterol Motil 2008;20:891–899.
44.
Perera MA, et al: Prediction of CYP3A4 enzyme activity using haplotype tag SNPs in African-Americans. Pharmacogenomics J 2009;9:49–60.
45.
Perera MA, et al: Prediction of CYP3A4 enzyme activity using haplotype tag SNPs in African-Americans. Pharmacogenomics J 2009;9:49–60.
46.
Ingelman-Sundberg M, et al: Influence of cytochrome P450 polymorphisms on drug therapies: pharmacogenetic, pharmacoepigenetic and clinical aspects. Pharmacol Ther 2007;116:496–526.
© 2009 S. Karger AG, Basel
2009
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.